Effect of albuterol on maximal exercise capacity in cystic fibrosis

Serisier, David J., Coates, Andrew D. and Bowler, Simon D. (2007) Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest, 131 4: 1181-1187. doi:10.1378/chest.06-1697


Author Serisier, David J.
Coates, Andrew D.
Bowler, Simon D.
Title Effect of albuterol on maximal exercise capacity in cystic fibrosis
Journal name Chest   Check publisher's open access policy
ISSN 0012-3692
Publication date 2007
Sub-type Article (original research)
DOI 10.1378/chest.06-1697
Volume 131
Issue 4
Start page 1181
End page 1187
Total pages 7
Place of publication United States
Publisher American College of Chest Physicians
Collection year 2008
Language eng
Subject 321027 Respiratory Diseases
320503 Clinical Pharmacology and Therapeutics
C1
730107 Inherited diseases (incl. gene therapy)
Formatted abstract
Background: Inhaled, short-acting β-adrenergic agonists (SAβAs) are widely prescribed in cystic fibrosis (CF) subjects, despite a lack of convincing data for efficacy and the potential for these agents to result in airway instability. We tested the hypothesis that inhaled albuterol would improve maximal exercise performance in CF subjects with airflow obstruction, as a result of acute bronchodilation.

Methods: Randomized, double-blind, placebo-controlled crossover study of the effect of inhaled albuterol on maximal exercise performance in 20 stable adult CF patients (mean ± SD age, 23.3 ± 6.1 years; FEV1, 57.65 ± 17.13% of predicted).

Results: Ventilatory limitation to exercise was demonstrated in 16 subjects (80%). Significant bronchodilation occurred with exercise alone (end-exercise FEV1, 2.24 ± 0.8 L; vs preexercise FEV1, 2.09 ± 0.77 L; p < 0.0001), but albuterol resulted in significantly greater exercise-induced bronchodilation than placebo (change in FEV1, 0.3 ± 0.15 L vs 0.15 ± 0.11 L; 95% confidence interval [CI], + 0.07 to + 0.23; p < 0.001). However, there was no difference in maximal workload achieved (albuterol, 158 ± 46 W; vs placebo, 158 ± 45 W; 95% CI, − 4.41 to + 4.71; p = 0.95), nor any other measure of exercise performance including maximal oxygen uptake.

Conclusions:
Despite causing significant acute bronchodilation, inhaled albuterol did not improve maximal exercise performance in ventilatory-limited CF adults, adding to the body of literature that fails to show any clinical benefit of SAβAs in CF subjects. The current results provide further evidence to question the widespread use of these agents, although the potential for adrenergic β-agonists to instead improve submaximal exercise performance merits further investigation.
Keyword adrenergic β-agonists
albuterol
cystic fibrosis
exercise
salbutamol
Q-Index Code C1
Q-Index Status Confirmed Code

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
2008 Higher Education Research Data Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 8 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 10 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 07 May 2008, 13:46:03 EST by Maree Knight on behalf of Faculty Of Health Sciences